| Revenue Growth | LUMVO generated $24.7 million in its first quarter of launch. |
|---|---|
| Mgmt Confidence | Extremely proud of start; firing on all cylinders; 100% committed. |
| Demand Visibility | Over 100 patients treated; 60-90 day enrollment-to-infusion timeline; no bolus observed. |
| Op. Leverage | Pipeline programs plug into established infrastructure with proven track record. |
| Vol vs Price | Demand-led growth with over 100 patients completing at least one infusion. |
| Segment Growth | LUMVO launch exceeded expectations; 2,000 core prescribers write 80% of scripts. |
| New Clients | Reached 90% of covered lives; 30% already have policy coverage. |
| Capex & Debt | $955 million in cash and marketable securities; funded through profitability. |
| Regulatory | CMS assigned permanent J-code effective January 1, 2027; BLA Q1 2027. |
| Commentary | Strategy focused on conversion of 2,000 core prescribers in established market. |
| New Launches | LUMVO launched; VRGN292 Phase 1 starting; VRGN008 data expected later quarter. |
Growth
LUMVO generated $24.7 million net product revenue in its first quarter post-approval.
Outlook
BLA submission for subcutaneous Velisig expected Q1 2027; broad payer coverage in 6-9 months.
Risks
Management used vague language regarding specific market share and exit velocity, citing early launch stages.
The company's earnings call, NASDAQ: VRDN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Viridian Therapeutics, Inc.\DE: key numbers
- Share price
- $29.80Close, Nov 16
- Market cap
- $3.38B
- Shares outstanding
- 113.56MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Viridian Therapeutics, Inc.\DE
All →Viridian Therapeutics, Inc.\DE Clinical Trial Data
Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.
Viridian Therapeutics, Inc.\DE Q3 2026 Results: Net Loss of $101M, Loss Widens
Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.
- Key figure
- Net loss $101M
Viridian Therapeutics, Inc.\DE Financial Results
Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”
Steve Mahoney, President and Chief Executive Officer